Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 572 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells October 15, 2019 Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom... July 4, 2023 New option to treat advanced oesophageal cancer approved for NHS in... August 11, 2021 How Having a Creative Outlet Helped Me Cope During Cancer November 8, 2022 Load more HOT NEWS The American Society of Clinical Oncology and the American Cancer Society:... Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December
